RESEARCH TRIANGLE PARK, N.C., Sept. 23 /PRNewswire/ -- Max Neeman International, a leading Indian CRO, announced a partnership with Max Healthcare to open a Phase I/IIa clinical trial unit at Max Super Speciality Hospital, New Delhi, India. This proof of concept unit will allow Pharmaceutical, Biotech & Device companies the option to complete a critical part of the development process across multiple therapeutic areas quickly and with the highest quality.
The new Phase I/IIa unit will evaluate compounds/devices developed both in India and in other countries. This unit will provide end-to-end services and will have approximately 24 beds, with plans to expand this number to 50 to meet predicted growth in demand.
This new Phase I/IIa unit will draw on the experience of its partners and the expertise of local clinicians and scientists to deliver studies in accordance with global standards and within the regulatory framework in India.
Our partner Max Healthcare, with over 800 beds and 8 hospitals in Delhi is one of the leading hospital chains in India and has an outstanding reputation and track record for quality health care provision in India.
About Max Healthcare
With over 800 beds and 8 hospitals in Delhi, and with over 1500 physicians and 3000 support staff - Max Healthcare is one of a leading chain of hospitals in India. Its state of the art infrastructure, over 225 ICU beds and most advanced technologies makes it one of the best hospitals in India. http://www.maxhealthcare.in
About Max Neeman International
Max Neeman International is one of the leading and largest CROs in India providing a full range of clinical services to global Pharmaceutical, Biotech and Device companies. Operational since 2001, it is an ISO 9001:2000 certified CRO for Monitoring, Site Management and Data Management Services. Presently, it is active in 22 cities with 5 regional offices. Please contact Donald Swankie, Vice President of Business Development for more information (email@example.com/ +1.919.424.3345). http://www.neeman-medical.com
|SOURCE Max Neeman International|
Copyright©2009 PR Newswire.
All rights reserved